CTOs on the Move

ICON Plc

www.iconplc.com

 
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialise in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies.    In a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis.    We have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. We are also an 'end-to-end' Pharmacovigilance ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.iconplc.com
  • 7740 Milestone Parkway Suite 150
    Hanover, MD USA 21076
  • Phone: 410.696.3000

Executives

Name Title Contact Details

Similar Companies

Alergan

Alergan is a Waco, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Entegrion

Entegrion is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Finishing Touch Salon

Finishing Touch Salon is a Waterbury, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nines

Nines is a dynamic team applying world-class ML and AI expertise to the field of medicine.

Providence Therapeutics

Providence is a clinical-stage biotechnology company pioneering mRNA therapeutics and vaccines with a focus on infectious diseases and oncology. Initially founded as a cancer vaccines company in 2015, in response to a worldwide need for a COVID-19 vaccine, Providence expanded its focus beyond oncology therapies to develop an mRNA vaccine for COVID-19. Providence works with multiple industry collaborators, universities, nongovernmental agencies and multiple arms of the Government of Canada to discover and develop vaccines and treatments for infectious diseases and cancer. This has resulted in the development of an mRNA vaccine platform that includes a proprietary design algorithm and proprietary, scalable manufacturing processes.